Standard BioTools and Treeline Biosciences to Merge in All-Stock Deal
Standard BioTools Inc. and Treeline Biosciences, Inc. announced a definitive merger agreement to combine in an all-stock transaction. The combined company will operate as Treeline Biosciences and will be led by Treeline's current CEO, Josh Bilenker. The merger is expected to create a well-capitalized biopharma company with over $900 million in cash at closing, providing runway into 2029. Treeline's pipeline includes several clinical-stage programs in oncology, neurology, and immunology, with anticipated data readouts starting in 2027. Standard BioTools will explore strategic options, including divestitures, for its Mass Cytometry and Microfluidics businesses, as Treeline does not intend to operate them. The transaction is expected to close in the second half of 2026.
Key Highlights
- Standard BioTools and Treeline Biosciences to combine in an all-stock merger.
- Combined company to operate as Treeline Biosciences, led by Treeline CEO Josh Bilenker.
- Pro forma combined company expected to have over $900 million in cash at closing, providing runway into 2029.
- Standard BioTools' Mass Cytometry and Microfluidics businesses will be explored for divestiture.
- Former Standard BioTools stockholders expected to hold ~16% and former Treeline stockholders ~84% of the combined company.
- Treeline's pipeline includes three Phase 1 programs with multiple anticipated clinical data readouts beginning in 2027.
- Transaction expected to close in the second half of 2026, subject to approvals.
Price Impact
More from LAB